BIGBEAR
PHARMACEUTICAL
Cobimetinib first received marketing authorization in the European Union in 2015. It is a highly selective, reversible allosteric inhibitor of mitogen-activated protein kinase (MEK) 1/2.
AuthenticGuaranteeFast DeliveryPrivacy As a potent and highly selective MEK1/2 inhibitor, the Lao Big Bear version of Cobimetinib has demonstrated a clinical response rate and safety profil···【More】
Update: 11 Jun,2026Source: BigbearViews: 73
The Laos Dabear version of Cobimetinib, as the first generic alternative to the original drug "Cobimetinib" in the Southeast Asian region, i···【More】
Update: 11 Jun,2026Source: BigbearViews: 73
With the accessibility of targeted anticancer drugs receiving increasing attention, the generic version of Cobimetinib launched by Lao Bear Pharmaceut···【More】
Update: 11 Jun,2026Source: BigbearViews: 74
Cobimetinib (Cotellic) is a targeted therapy for the treatment of melanoma with BRAF V600 mutation. Reliable procurement channels and standardized adm···【More】
Update: 28 Feb,2026Source: BigbearViews: 106
Cobimetinib is a targeted therapy for melanoma with BRAF V600E/K mutation. The dosage per treatment cycle and treatment cost are key concerns for pati···【More】
Update: 28 Feb,2026Source: BigbearViews: 110
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
